Generic drugs flooding the market destroying the miraculous weight loss drug! After losing $70 billion in market value in one day, Barclays warns that Novo Nordisk (NVO.US) faces a "credibility collapse".

Zhtng cijng APP zhy do, nu h nu d (NVO.US) gji zhusn chx xicu. Zh ji jinfi shnyo Wegovy de zhzo shngchng qin ytin gnggng fb yngl yqng bng rnmng xn CEO, dozh shzh zhngf 700 y miyun, r fnxsh jnggo chng migu shchng fngzhyo de chx jngzhng jingdi li yl. The Zhtng Finance APP noticed that the stock price of Novo Nordisk (NVO.US) continued to decline on Wednesday. The manufacturer of the weight-loss drug Wegovy issued a profit warning the previous day and appointed a new CEO, leading to a market capitalization loss of $70 billion, while analysts warned that continued competition in the U.S. generic drug market would bring pressure.